Biopharma's Reputation Problem
Erik Clausen
Strategic Communications Leader | Precision Medicine + Life Science | Ally
The pharmaceutical industry is on a streak. Unfortunately, it's not an enviable one.?
For several years, pharma has been the most poorly regarded industry in Americans' eyes, ranking last on a list of 25 sectors that Gallup tests annually in national?polling. In 2023, Americans are more than three times as likely to rate the pharmaceutical industry negatively (60 percent) as positively (18 percent), giving it a net-positive score of -42.
For a frame of reference, the federal government has a more favorable rating than biopharma. Let that sink in.
However, you might ask, so what? Who cares what the average American thinks about the industry?
Well, you might care if you are recruiting "average Americans" for a clinical trial, to invest when you take your company public or are seeking top talent that might decide to take their skills elsewhere. Or if you expect your industry to be dragged in front of Congress for hearings on drug pricing during an election year. (Spoiler alert: you can expect this in a few months.)
领英推荐
Growing a positive corporate reputation is crucial for biopharma. It should be an obvious priority, given that a commitment to patient well-being is why the industry exists. These profoundly moving and positive human stories are the north star AND hold the secret to saving the industry's image problem.
To this end, there are a few strategies for biopharma companies to enhance their reputation:
Building a positive corporate reputation takes time, consistency, and a commitment to ethical and responsible practices. But it will open doors for the?organization and can function as a "social credit" to fall back on when crises?or challenges emerge.?
Good reputations are built on character, communication, and consistency but are fragile things. As Warren Buffett said, "It takes twenty years to build a reputation and five minutes to ruin it."
So hard to read. I have so many friends, colleagues and clients in the life sciences and the motivation to heal is so strong. I agree- helping people see the good is critical.
Enabling BioPharma to Deliver Life-Changing Therapies Worldwide
1 年Yes the IRA will further bring that down. Profitability of pharma would be challenged whether it fulfill it's mission to investors or truly doing good for mankind. Truly unique and challenging for biopharma to keep yielding profits while recouping RD on its early work and increasing accessibility to patient. Interesting how the post AGI economy will ease this burden.